Valneva SE (EPA:VLA)
2.378
-0.017 (-0.71%)
Jun 3, 2026, 5:35 PM CET
Valneva SE Employees
Valneva SE had 674 employees as of December 31, 2025. The number of employees decreased by 39 or -5.47% compared to the previous year.
Employees
674
Change
-39
Growth
-5.47%
Revenue / Employee
€231,945
Profits / Employee
€204,797
Market Cap
454.20M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 674 | -39 | -5.47% |
| Jun 30, 2025 | 700 | - | - |
| Dec 31, 2024 | 713 | 37 | 5.47% |
| Dec 31, 2023 | 676 | -43 | -5.98% |
| Dec 31, 2022 | 719 | -43 | -5.64% |
| Dec 31, 2021 | 762 | 262 | 52.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Genfit | 188 |
| Innate Pharma | 164 |
| DBV Technologies | 161 |
| MedinCell | 145 |
| Transgene | 145 |
| Nanobiotix | 100 |
| Inventiva | 77 |
Valneva SE News
- 6 hours ago - Valneva SE Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 13 hours ago - Valneva SE Slides: Investor presentation - Filings
- 6 days ago - Valneva to Participate at U.S. and European Investor Conferences in June - GlobeNewsWire
- 21 days ago - Valneva Q1 Earnings Call Highlights - MarketBeat
- 21 days ago - Valneva SE Earnings Call Transcript: Q1 2026 - Transcripts
- 21 days ago - Valneva SE Earnings release: Q1 2026 - Filings
- 21 days ago - Valneva SE Slides: Q1 2026 - Filings
- 21 days ago - Valneva SE Quarterly report: Q1 2026 - Filings